	IOMS F	OF	<u>۲۱</u>			
SUSPECT ADVERSE REACTION REPORT						
		П	Г			
I. REACTION INFORMATION						
(first, last) Pour Month   Year APPR	APPROPRIATE TO					
PRIVACY COSTA RICA PRIVACY Unk Female Unk Day Month Unk Pear ADVE	RSE REA	CH	OI			
7 + 13 DESCRIBE REACTION(S) (including relevant tests/lab data)  Event Verbatim [PREFERRED TERM] (Related Product Socious Listed Reporter Company   INVOLVE	-D OB					
symptoms if any separated by commas)  The pharmacy dispensed Xigduo 10mg/1000mg  HOSPITA	INVOLVED OR PROLONGED INPATIENT HOSPITALISATION					
instead of Xigduo 5mg/1000mg (medication error). [Product dispensing error] XIGDUO No		۱T				
INCAPA(	YTK					
☐ THREAT						
CONGE!						
(Continued on Additional Information Page)						
II. SUSPECT DRUG(S) INFORMATION						
	ON ER STOPPING					
(Continued on Additional Information Page)						
15. DAILY DOSE(S) #1 ) 5mg/1000mg   16. ROUTE(S) OF ADMINISTRATION #1 ) Oral use   YES [	NO NA					
17. INDICATION(S) FOR USE  #1 ) Diabetes (Diabetes mellitus)  21. DID REACTION REAPPEAR REINTRODUCTION	AFTER					
18. THERAPY DATES(from/to)						
III. CONCOMITANT DRUC(S) AND HISTORY						
III. CONCOMITANT DRUG(S) AND HISTORY  22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction)						
23. OTHER RELEVANT HISTORY. (e.g. diagnostics, allergies, pregnancy with last month of period, etc.)						
From/To Dates Type of History / Notes Description Unknown Indication Diabetes (Diabetes)						
IV. MANUFACTURER INFORMATION						
24a. NAME AND ADDRESS OF MANUFACTURER 26. REMARKS AstraZeneca 26. REMARKS World Wide #: CR-ASTRAZENECA-202507CAM01404						
Serban Ghiorghiu Study ID: PSP-23269	Study ID: PSP-23269					
Medimmune way Saithersburg, Maryland 20878 UNITED STATES Phone: +1 301-398-0000  Case References: CR-AstraZeneca-CH-00912904A						
			_			
24b. MFR CONTROL NO. 25b. NAME AND ADDRESS OF REPORTER  202507CAM014041CR NAME AND ADDRESS WITHHELD.	NAME AND ADDRESS WITHHELD.					
<u> </u>						
24c. DATE RECEIVED BY MANUFACTURER 24d. REPORT SOURCE STUDY  AME AND ADDRESS WITHHELD.						
24c. DATE RECEIVED BY MANUFACTURER 17-JUL-2025  24d. REPORT SOURCE STUDY LITERATURE HEALTH PROFESSIONAL OTHER:						

X INITIAL

FOLLOWUP:

Mfr. Control Number: 202507CAM014041CR

## **ADDITIONAL INFORMATION**

## 7+13. DESCRIBE REACTION(S) continued

Case Description: A solicited report has been received from a consumer in Patient Support Program. The report concerns a female patient born in 1956.

No medical history was reported.

No concomitant products were reported.

The patient started treatment with Xigduo (dapagliflozin, metformin) (batch number(s) Unknown) 5 milligram qd, Oral use, on an unknown date for diabetes.

On an unknown date, the patient experienced the pharmacy dispensed xigduo 10mg/1000mg instead of xigduo 5mg/1000mg (medication error). (preferred term: Product dispensing error).

The outcome of the event(s) of the pharmacy dispensed xigduo 10mg/1000mg instead of xigduo 5mg/1000mg (medication error). was unknown.

The event was considered non-serious.

The reporter did not assess causality for the pharmacy dispensed xigduo 10mg/1000mg instead of xigduo 5mg/1000mg (medication error)..

This case was marked as suppressed due to Medication Error with no AE.

## 14-19. SUSPECT DRUG(S) continued

14. SUSPECT DRUG(S) (include generic name)	15. DAILY DOSE(S); 16. ROUTE(S) OF ADMIN	17. INDICATION(S) FOR USE	18. THERAPY DATES (from/to); 19. THERAPY DURATION
#1 ) XIGDUO (DAPAGLIFLOZIN,	10mg/1000mg; Oral use	Diabetes (Diabetes mellitus)	Unknown;
METFORMIN) Tablet; Regimen #2			Unknown